The agreement with Royalty Pharma to monetize up to $1.5 billion of the Evrysdi Royalty Stream is a significant financial move for PTC Therapeutics. This deal is likely to provide the company with a substantial cash inflow, which could be used for further research and development, or to strengthen its balance sheet. As a result, investors are reacting positively, leading to an increase in the company's share price.